Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To determine the transfer of rituximab, an anti-CD20 monoclonal antibody widely used for neurologic conditions, into mature breast milk. Methods Breast milk samples were collected from 9 women with MS who received rituximab 500 or 1,000 mg intravenous once or twice while breastfeeding from November 2017 to April 2019. Serial breast milk samples were collected before infusion and at 8 hours, 24 hours, 7 days, and 18–21 days after rituximab infusion in 4 patients. Five additional patients provided 1–2 samples at various times after rituximab infusion. Results The median average rituximab concentration in mature breast milk was low at 0.063 μg/mL (range 0.046–0.097) in the 4 patients with serial breast milk collection, with an estimated median absolute infant dose of 0.0094 mg/kg/d and a relative infant dose (RID) of 0.08% (range 0.06%–0.10%). Most patients had a maximum concentration at 1–7 days after infusion. The maximum concentration occurred in a woman with a single breast milk sample and was 0.29 μg/mL at 11 days postinfusion, which corresponds with an estimated RID of 0.33%. Rituximab concentration in milk was virtually undetectable by 90 days postinfusion. Conclusions We determined minimal transfer of rituximab into mature breast milk. The RID for rituximab was less than 0.4% and well below theoretically acceptable levels of less than 10%. Low oral bioavailability would probably also limit the absorption of rituximab by the newborn. In women with serious autoimmune neurologic conditions, monoclonal antibody therapy may afford an acceptable benefit to risk ratio, supporting both maternal treatment and breastfeeding.Keywords
This publication has 27 references indexed in Scilit:
- Suppression of normal immune responses after treatment with rituximabCurrent Opinion in Rheumatology, 2016
- Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humansNutrition Journal, 2015
- Transfer of Natalizumab into Breast Milk in a Mother with Multiple SclerosisJournal of Human Lactation, 2015
- Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysisZeitschrift für Neurologie, 2014
- Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugsJournal of Neurology, Neurosurgery & Psychiatry, 2014
- Chemotherapy, targeted agents, antiemetics and growth-factors in human milk: How should we counsel cancer patients about breastfeeding?Cancer Treatment Reviews, 2013
- Breastfeeding and the Use of Human MilkPEDIATRICS, 2012
- Perspectives on Immunoglobulins in Colostrum and MilkNutrients, 2011
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple SclerosisThe New England Journal of Medicine, 2008
- Breastfeeding and the Use of Human MilkPEDIATRICS, 2005